{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:42Z","timestamp":1792787262549,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01183"],"award-info":[{"award-number":["2020-01183"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-0191"],"award-info":[{"award-number":["2023-0191"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fredrik & Ingrid Thuring Foundation","award":["2023-009"],"award-info":[{"award-number":["2023-009"]}]},{"name":"ALF Region V\u00e4sterbotten","award":["RV-993186"],"award-info":[{"award-number":["RV-993186"]}]},{"name":"Region Stockholm","award":["FoUI-987637"],"award-info":[{"award-number":["FoUI-987637"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dr Margaretha Nilsson Foundation","award":["802480-5718"],"award-info":[{"award-number":["802480-5718"]}]},{"name":"ALF Region Stockholm","award":["FoUI-985921"],"award-info":[{"award-number":["FoUI-985921"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ume\u00e5 University Strategic Research Grants","award":["978634"],"award-info":[{"award-number":["978634"]}],"id":[{"id":"https:\/\/ror.org\/05kb8h459","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Spjutspetsmedel Region V\u00e4sterbotten","award":["RV-1004927"],"award-info":[{"award-number":["RV-1004927"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compulsive sexual behaviour disorder (CSBD), characterised by preoccupation with and loss of control over sexual behaviours, is associated with negative consequences in several areas of life. Evidence for pharmacological treatment remains limited, with only two previous randomised controlled trials and no studies comparing fluoxetine and naltrexone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether naltrexone was more efficient and tolerable than fluoxetine in the treatment of CSBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label superiority trial, 80 participants diagnosed with CSBD according to International Classification of Diseases-11 criteria were randomly assigned (1:1) to receive fluoxetine (starting dose 20\u2009mg\/day) or naltrexone (starting dose 25\u2009mg\/day) for 8 weeks followed by 6 weeks without treatment. Symptom severity was recurringly assessed using the Hypersexual Disorder: Current Assessment Scale (HD:CAS). Linear mixed models were used for intention-to-treat and per-protocol analyses of treatment effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>79 men and 1 woman were randomised to receive fluoxetine (n=40) or naltrexone (n=40). Analysis showed no statistically significant difference in HD:CAS score reduction between treatments at primary endpoint; naltrexone was not superior to fluoxetine. However, participants in the two treatment groups showed different patterns of symptom improvement over time.<\/jats:p>\n                    <jats:p>Two participants (5.1%) receiving fluoxetine were withdrawn due to adverse events (urticaria and elevated liver enzymes) and four participants (10.3%) discontinued treatment; six participants (15%) receiving naltrexone discontinued treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although no statistically significant between-group difference was observed at week 8, symptom trajectories and adverse effect profiles differed between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Symptom-change patterns and adverse effect profiles may guide individualised treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302953","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:30Z","timestamp":1791303030000},"page":"e302953","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-4109","authenticated-orcid":false,"given":"Josephine","family":"Savard","sequence":"first","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Clinical Sciences (Psychiatry), Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6361-7862","authenticated-orcid":false,"given":"Marta","family":"Piwowar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberth","family":"Adebahr","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences (Psychiatry), Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-8119","authenticated-orcid":false,"given":"Markus","family":"Bystr\u00f6m","sequence":"additional","affiliation":[{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"},{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hallberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Dhejne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"G\u00f6rts \u00d6berg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden"},{"name":"ANOVA, Karolinska University Hospital, Stockholm, Stockholm County, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Jokinen","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences (Psychiatry), Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2026100609101863000_29.1.e302953.1","unstructured":"World Health Organization . International classification of diseases, eleventh revision (ICD-11), World Health Organization (WHO) 2019\/2021. 2024. Available: https:\/\/icd.who.int\/browse\/2025-01\/mms\/en#1630268048"},{"key":"2026100609101863000_29.1.e302953.2","doi-asserted-by":"crossref","first-page":"102355","DOI":"10.1016\/j.cpr.2023.102355","article-title":"Empirically-based dynamic risk and protective factors for sexual offending","volume":"106","author":"Seto","year":"2023","journal-title":"Clin Psychol Rev"},{"key":"2026100609101863000_29.1.e302953.3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1556\/2006.2022.00060","article-title":"Who feels affected by \u201cout of control\u201d sexual behavior? Prevalence and correlates of indicators for ICD-11 Compulsive Sexual Behavior Disorder in the German Health and Sexuality Survey (GeSiD)","volume":"11","author":"Briken","year":"2022","journal-title":"J Behav Addict"},{"key":"2026100609101863000_29.1.e302953.4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/19585969.2022.2134739","article-title":"The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder","volume":"24","author":"Turner","year":"2022","journal-title":"Dialogues Clin Neurosci"},{"key":"2026100609101863000_29.1.e302953.5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1080\/00224499.2023.2282619","article-title":"No Magic Pill: A Systematic Review of the Pharmacological Treatments for Compulsive Sexual Behavior Disorder","volume":"61","author":"Borgogna","year":"2024","journal-title":"J Sex Res"},{"key":"2026100609101863000_29.1.e302953.6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40263-024-01075-2","article-title":"Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options","volume":"38","author":"Mestre-Bach","year":"2024","journal-title":"CNS Drugs"},{"key":"2026100609101863000_29.1.e302953.7","unstructured":"Electronic medicines compendium: fluoxetine 20 mg summary of product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/13515\/smpc [Accessed 1 Jun 2025]."},{"key":"2026100609101863000_29.1.e302953.8","first-page":"10","article-title":"Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients","volume":"62","author":"Montejo","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2026100609101863000_29.1.e302953.9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.jsxm.2020.04.318","article-title":"Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men","volume":"17","author":"Savard","year":"2020","journal-title":"J Sex Med"},{"key":"2026100609101863000_29.1.e302953.10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/wps.21026","article-title":"Tolerability and efficacy of paroxetine and naltrexone for treatment of compulsive sexual behaviour disorder","volume":"21","author":"Lew-Starowicz","year":"2022","journal-title":"World Psychiatry"},{"key":"2026100609101863000_29.1.e302953.11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1218"},{"key":"2026100609101863000_29.1.e302953.12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jsxm.2021.06.008","article-title":"Reaching Men and Women at Risk of Committing Sexual Offences - Findings From the National Swedish Telephone Helpline PrevenTell","volume":"18","author":"Adebahr","year":"2021","journal-title":"J Sex Med"},{"key":"2026100609101863000_29.1.e302953.13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/26929953.2024.2392204","article-title":"Paraphilias and Sexual Offending in Compulsive Sexual Behavior in the Sex@Brain-Study","volume":"32","author":"Engel","year":"2025","journal-title":"Sexual Health & Compulsivity"},{"key":"2026100609101863000_29.1.e302953.14","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2026100609101863000_29.1.e302953.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051756","article-title":"A randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder: presentation of the study protocol","volume":"12","author":"Savard","year":"2022","journal-title":"BMJ Open"},{"key":"2026100609101863000_29.1.e302953.16","unstructured":"Kafka MP . Proposed dimensional measures for hypersexual disorder: the Hypersexual Disorder Screening Inventory (HDSI) and the Hypersexual Disorder Current Assessment Scale (HD:CAS). Prepared by the Paraphilias Subworkgroup of the Work Group on Sexual and Gender Identity Disorders for DSM-V. 2009;Pre-print."},{"key":"2026100609101863000_29.1.e302953.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-009-9574-7"},{"key":"2026100609101863000_29.1.e302953.18","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jsxm.2020.07.018","article-title":"Internet-Administered Cognitive Behavioral Therapy for Hypersexual Disorder, With or Without Paraphilia(s) or Paraphilic Disorder(s) in Men: A Pilot Study","volume":"17","author":"Hallberg","year":"2020","journal-title":"J Sex Med"},{"key":"2026100609101863000_29.1.e302953.19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jsxm.2019.03.005","article-title":"A Randomized Controlled Study of Group-Administered Cognitive Behavioral Therapy for Hypersexual Disorder in Men","volume":"16","author":"Hallberg","year":"2019","journal-title":"J Sex Med"},{"key":"2026100609101863000_29.1.e302953.20","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)","volume":"55 Suppl 44","author":"Lindstr\u00f6m","year":"2001","journal-title":"Nord J Psychiatry"},{"key":"2026100609101863000_29.1.e302953.21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"2026100609101863000_29.1.e302953.22","unstructured":"Electronic Medicines Compendium . Naltrexone hydrochloride 50 mg film-coated tablets summary of product characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/8968\/smpc [Accessed 1 Jun 2025]."},{"key":"2026100609101863000_29.1.e302953.23","first-page":"166","article-title":"Should compulsive sexual behavior (CSB) be considered as a behavioral addiction? A debate paper presenting the opposing view","volume":"11","author":"Sassover","year":"2022","journal-title":"J Behav Addict"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:35Z","timestamp":1791303035000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,6]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjment-2026-302953"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302953","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}